

## GlobelImmune Inc

### COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 06-Jul-2015

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 8

Product Portfolio Summary..... 12

Product Portfolio Drugs..... 17

[Return to Table of Contents](#)

# GlobelImmune Inc

## COMPANY OVERVIEW

<b>Company Name</b>	GlobelImmune Inc
<b>Parent Company Name</b>	GlobelImmune Inc
<b>Website</b>	<a href="http://www.globeimmune.com/">http://www.globeimmune.com/</a>
<b>Country</b>	US
<b>Number of Drugs in Active Development</b>	6
<b>Number of Inactive Drugs</b>	12
<b>Number of Patents as Owner</b>	20
<b>Number of Patents as Third Party</b>	2
<b>Number of Deals</b>	9
<b>Key Indications</b>	Breast tumor,Chordoma,HIV infection,Hepatitis D virus infection,Mycobacterium tuberculosis infection,Non-small-cell lung cancer,Pancreas tumor,Colorectal tumor,Medullary thyroid cancer,Hepatitis B
<b>Key Target-based Actions</b>	Mucin 1 stimulator,CD66e modulator,Hepatitis C virus NS3 protease modulator,Brachyury protein modulator,CD95 agonist,Epidermal growth factor receptor modulator,HIV GAG protein modulator,PARP inhibitor,Protease inhibitor,Ras GTPase modulator,SETX gene modulator
<b>Key Technologies</b>	Yeast recombinant,Biological therapeutic,Antigen presentation system,Parenteral formulation unspecified,Subcutaneous formulation,Tumor antigen therapeutic,Small molecule therapeutic,Viral core protein,Protein fusion,Antigen,Drug combination,Peptide,Tumor antigen

## COMPANY PROFILE

### SUMMARY

GlobelImmune Inc is a biopharmaceutical company which is engaged in the discovery, development and manufacturing of potent, targeted molecular immunotherapies, named Tarmogens, for the treatment of cancer and infectious diseases. Tarmogens are whole, heat-killed recombinant *Saccharomyces cerevisiae* yeast which has been genetically modified to express protein targets. They taken up by antigen presenting cells, and stimulate a cytotoxic T lymphocytes against cells expressing the desired target.

### COMPANY LOCATION

In December 2005, GlobelImmune relocated its headquarters to Louisville, CO.

### TECHNOLOGY INFORMATION

Tarmogens are whole, heat-killed, recombinant *Saccharomyces cerevisiae* engineered to produce one or more target disease proteins or antigens that stimulate the immune system against diseased cells.

### LICENSING AGREEMENTS

In May 2009, GlobelImmune granted exclusive license to all their oncology programs, including GI-4000 immunotherapies, to Celgene, for which GlobelImmune will receive a \$40 million upfront payment from Celgene. GlobelImmune will conduct the early development of the product candidates through certain pre-defined endpoints. Celgene will have the option to obtain an exclusive worldwide license to develop and commercialize these immunotherapy product candidates. GlobelImmune is eligible to receive over \$500 million in development and regulatory milestones, double-digit royalties and additional milestone payments based on net sales of the licensed product candidates.

In July 2008, GlobelImmune and the National Cancer Institute (NCI) at the National Institutes of Health (NIH) signed a CRADA to jointly develop Tarmogen based immunotherapy products for cancer. GlobelImmune would use its Tarmogen technology to develop the products which would express cancer antigens provided by the NIH. The NIH would conduct and fund preclinical and early clinical development of the product candidates. CEA (carcinoembryonic antigen) was the

[Return to Table of Contents](#)

first cancer antigen to be evaluated in this collaboration.

In January 2005, GlobelImmune and MycoLogics Inc signed a non-exclusive research license and option agreement. MycoLogics was to undertake proof-of-concept preclinical tests of vaccines targeting aspergillosis, coccidioidmycosis, cryptococcosis leishmaniasis, discovered using GlobelImmune's Tarmogen technology. The research was supported by NIH SBIR and STTR awards.

## FINANCIAL

In July 2014, the company planned to conduct an IPO of 1.5 million shares priced at \$10 each for gross proceeds of \$15 million. Underwriters would be granted a 45-day overallotment option to purchase up to 225,000 additional shares. The stock was approved to be listed on the NASDAQ Capital Market and trading of shares began under the ticker symbol 'GBIM'. At that time, the offering was expected to close on July 08, 2014. Later that month, the company raised gross proceeds of \$17.25 million from the offering of 1.725 million shares.

In July 2012, the company filed a common stock IPO registration statement with the US Security and Exchange Commission. At that time, the company also filed for its common stock to be listed on the NASDAQ Global Market under the symbol "GBIM".

In January 2010, GlobelImmune raised \$17.5 million from a series E preferred stock financing round.

In September 2007, GlobelImmune closed a \$41.2 million series C preferred stock financing round.

In January 2006, GlobelImmune completed a second closing of its series B preferred stock financing, raising a further \$4.1 million in addition to the previous \$34.3 million. The Company would use the funds to finish a phase II trial of GI-4000 for pancreatic cancer, and a phase Ib trial of GI-5005 for chronic hepatitis C infection.

In June 2003, GlobelImmune closed a series A preferred venture financing round. The round provided for up to \$8 million in two tranches, with closure of the second tranche dependent on achievement of certain milestones.

## COMPANY FINANCIALS

### SHARE INFORMATION

<b>Close Price (USD)</b>	2.55
<b>Change (USD)</b>	-0.03 (-1.17%)
<b>Previous Close Price (USD)</b>	2.58
<b>Volume</b>	14,746
<b>52-Week High (USD)</b>	15.00
<b>52-Week Low (USD)</b>	2.50
<b>Date</b>	02-Jul-2015
<b>Exchange</b>	NASDAQ(COMPOSITE)
<b>Current Number of Shares Outstanding</b>	5,751,574
<b>Current Market Capitalization</b>	14,666,514
<b>EPS (Date Reported)</b>	-8.04025

[Return to Table of Contents](#)

## STOCK PERFORMANCE



## MAJOR SHAREHOLDERS

Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
Biotechnology Value Fund, Inc.	Hedge Fund	United States	678,400	11.8	678,400	1	05-Jun-2015
Sequel Venture Partners	Venture Capital	United States	332,606	5.78	75,000	0.29	15-May-2015
Lilly Ventures	Venture Capital	United States	267,894	4.66	85,000	0.46	15-May-2015
Mitchell (Daniel J)	Individual Investor	United States	10,000	0.17	10,000	1	15-May-2015
Rodell (Timothy C)	Individual Investor	United States	6,904	0.12	5,000	2.63	15-May-2015
Geode Capital Management, L.L.C.	Investment Advisor/Hedge Fund	United States	5,000	0.09	0	0	31-May-2015
Fidelity Spartan Extended Market Index Fund	Mutual Fund	United States	5,000	0.09	0	0	31-May-2015

[Return to Table of Contents](#)





The Vanguard Group, Inc.	Investment Advisor	United States	4,718	0.08	1,900	0.67	31-May-2015
Vanguard Extended Market Index Fund	Mutual Fund	United States	2,400	0.04	1,900	3.8	31-May-2015
Christoffersen Kirk A	Individual Investor	United States	2,389	0.04	2,389	1	15-May-2015
Vanguard Total Stock Market Index Fund	Mutual Fund	United States	2,318	0.04	0	0	31-May-2015

## FINANCIAL PERFORMANCE



	2010	2011	2012	2013	2014
<b>Sales (USD M)</b>	4.067797	5.107842	14.641606	22.518369	5.966381
<b>Operating Income (USD M)</b>	-15.754804	-12.59346	-3.966484	7.687692	-5.819118
<b>Net Income (USD M)</b>	-14.791697	-13.724813	-2.014744	9.476699	-16.260926

[Return to Table of Contents](#)

## Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2015 Q1	1.187825	-1.560528	-1.560528
2014 Q4	1.510679	-1.74149	-1.74149
2014 Q3	1.306338	-1.5364	-6.659702
2014 Q2	1.731018	-1.336297	-9.151511
2014 Q1	1.418346	-1.204931	-5.882124
2013 Q3	2.331435	-1.246806	-3.927348
2013 Q2	4.222197	0.597252	-2.140577
2013 Q1	2.132267	-2.038215	-4.772857
2012 Q2	3.041572	-1.320637	-4.055256
2012 Q1	2.647035	-1.633175	-5.27658

## BALANCE SHEET

### Assets (USD M)

	2010	2011	2012	2013	2014
Cash & Short Term Investments	20.291374	15.154611	2.002948	5.924241	16.812459
Inventories - Total	0	0	0	0	0
Current Assets - Total	20.684243	15.576588	2.889343	6.825137	17.812351
Property, Plant And Equipment - Net	2.887816	2.068493	1.251848	0.492802	0.455768
Other Assets - Total	0	0	0.1	0.1	0.1
Total Assets	23.672059	17.745081	4.241191	7.417939	18.368119

[Return to Table of Contents](#)

## Liabilities (USD M)

	2010	2011	2012	2013	2014
Accounts Payable	1.132584	1.314915	2.957234	1.736621	0.572586
Short Term Debt & Current Portion Of Long Term Debt	0	0	0	0	0
Current Liabilities - Total	6.402923	13.442279	8.350924	6.414495	5.172489
Long Term Debt	0	0	0	0.197955	0
Other Liabilities	4.169498	5.152976	3.423218	1.787957	0.148641
Total Liabilities	30.066973	37.504009	25.568849	19.057383	12.764628

## Stockholders Equity (USD M)

	2010	2011	2012	2013	2014
Minority Interest	0	0	0	0	0
Preferred Stock	154.138153	164.927649	174.797249	187.68239	0
Common Stock	0.000377	0.000378	0.000397	0.000399	0.005752
Treasury Stock	0	0			
Total Liabilities & Shareholders' Equity	23.672059	17.745081	4.241191	7.417939	18.368119


[Return to Table of Contents](#)

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

## Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	3	6	9
Infectious disease	3	6	9
Gastrointestinal disease	2	2	4
Respiratory disease	2	2	4
Inflammatory disease	1	2	3
Endocrine disease	2	1	3
Dermatological disease	0	2	2
Gynecology and obstetrics	1	1	2
Immune disorder	0	2	2
Nutritional disorder	0	1	1
Musculoskeletal disease	1	0	1
Hematological disease	0	1	1
Neurological disease	0	1	1

## Drugs by Highest Status

### Active Drugs by Highest Status Chart



[Return to Table of Contents](#)

## Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	3
Discovery	3
Discontinued	1
No Development Reported	11

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Discovery/Design	1	0	0	0	1
Drug - Funding	3	0	0	0	3
Drug - CRADA	1	0	0	0	1
Drug - Early Research/Development	0	0	1	0	1
Drug - Development/Commercialization License	1	0	0	0	1
Drug - Development Services	1	0	1	0	2

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	2	7
Gastrointestinal disease	0	5
Respiratory disease	0	2
Inflammatory disease	0	2
Infectious disease	0	2
Endocrine disease	0	1
Musculoskeletal disease	1	1

### Trials by Phase

Phase	Ongoing	All
Phase 2	1	6

[Return to Table of Contents](#)



Phase 1	1	3
---------	---	---

## Phase Definitions

### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	0	1	1
Endocrine disease	3	0	3
Gastrointestinal disease	7	0	7
Genitourinary disease	2	0	2
Hematological disease	0	1	1
Degeneration	1	0	1
Andrology	1	0	1
Immune disorder	1	1	2
Musculoskeletal disease	1	0	1
Neoplasm	11	0	11
Ocular disease	0	1	1
Neurological disease	2	1	3
Nutritional disorder	1	0	1
Prophylaxis	1	0	1
Respiratory disease	5	0	5
Infectious disease	15	1	16
Inflammatory disease	7	1	8
Gynecology and obstetrics	2	0	2
Dermatological disease	1	0	1

[Return to Table of Contents](#)



\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.



## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### GI-4000

<b>Drug Name</b>	GI-4000
<b>Key Synonyms</b>	
<b>Originator Company</b>	GlobelImmune Inc
<b>Active Companies</b>	GlobelImmune Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Non-small-cell lung cancer, Pancreas tumor, Colorectal tumor
<b>Target-based Actions</b>	Ras GTPase modulator
<b>Other Actions</b>	Recombinant fungal vector vaccine, Therapeutic vaccine, Anticancer
<b>Technologies</b>	Tumor antigen therapeutic, Antigen presentation system, Yeast recombinant, Subcutaneous formulation, Biological therapeutic
<b>Last Change Date</b>	09-Apr-2014

### GI-6207

<b>Drug Name</b>	GI-6207
<b>Key Synonyms</b>	
<b>Originator Company</b>	GlobelImmune Inc
<b>Active Companies</b>	Celgene Corp, GlobelImmune Inc, National Cancer Institute
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Medullary thyroid cancer
<b>Target-based Actions</b>	CD66e modulator
<b>Other Actions</b>	Anticancer, Therapeutic vaccine, Recombinant vector vaccine
<b>Technologies</b>	Yeast recombinant, Subcutaneous formulation, Biological therapeutic
<b>Last Change Date</b>	15-May-2015

[Return to Table of Contents](#)

## GI-6301

<b>Drug Name</b>	GI-6301
<b>Key Synonyms</b>	
<b>Originator Company</b>	GlobelImmune Inc
<b>Active Companies</b>	Celgene Corp, GlobelImmune Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Breast tumor, Chordoma
<b>Target-based Actions</b>	Brachyury protein modulator
<b>Other Actions</b>	Anticancer, Recombinant fungal vector vaccine, Therapeutic vaccine, Immunostimulant
<b>Technologies</b>	Antigen presentation system, Yeast recombinant, Subcutaneous formulation, Biological therapeutic
<b>Last Change Date</b>	28-Apr-2015

## GI-2010

<b>Drug Name</b>	GI-2010
<b>Key Synonyms</b>	
<b>Originator Company</b>	GlobelImmune Inc
<b>Active Companies</b>	GlobelImmune Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	HIV infection
<b>Target-based Actions</b>	HIV GAG protein modulator
<b>Other Actions</b>	Immunostimulant, Antiviral, Therapeutic vaccine, Recombinant fungal vector vaccine
<b>Technologies</b>	Antigen presentation system, Viral core protein, Yeast recombinant, Biological therapeutic, Parenteral formulation unspecified
<b>Last Change Date</b>	19-Nov-2013

[Return to Table of Contents](#)



## GI-18000

<b>Drug Name</b>	GI-18000
<b>Key Synonyms</b>	
<b>Originator Company</b>	GlobelImmune Inc
<b>Active Companies</b>	GlobelImmune Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Hepatitis D virus infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Anti-inflammatory, Unspecified drug target, Antiviral
<b>Technologies</b>	Antigen presentation system, Yeast recombinant, Biological therapeutic, Parenteral formulation unspecified
<b>Last Change Date</b>	19-Nov-2013

## GI-19000

<b>Drug Name</b>	GI-19000
<b>Key Synonyms</b>	
<b>Originator Company</b>	GlobelImmune Inc
<b>Active Companies</b>	GlobelImmune Inc, Colorado State University
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Mycobacterium tuberculosis infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Antibacterial, Prophylactic vaccine, Therapeutic vaccine, Unspecified drug target
<b>Technologies</b>	Yeast recombinant, Biological therapeutic, Parenteral formulation unspecified
<b>Last Change Date</b>	20-Jan-2015

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

